Recombinant Human Thrombopoietin
drugOn this page
Also known as C-mpl ligandMegakaryocyte stimulating factorMegapoietinRh-tpoThrombopoietin
Summary
Recombinant Human Thrombopoietin (CHEMBL4802180) is a phase-3 clinical-stage unknown; indicated across 13 conditions including autoimmune thrombocytopenic purpura and acute myeloid leukemia.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 13 conditions
- Clinical trials: 14
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4802180 |
| Name | Recombinant Human Thrombopoietin |
| Type | Unknown |
| Max phase | 3 |
Also known as: C-mpl ligand, Megakaryocyte stimulating factor, Megapoietin, Recombinant human thrombopoietin, Rh-tpo, Thrombopoietin, RECOMBINANT HUMAN THROMBOPOIETIN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
13 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| autoimmune thrombocytopenic purpura | 3 | MONDO:0008558 | EFO:0007160 |
| acute myeloid leukemia | 3 | MONDO:0018874 | EFO:0000222 |
| sarcoma | 3 | MONDO:0005089 | EFO:0000691 |
| thrombocytopenia | 3 | MONDO:0002049 | HP:0001873 |
| graft versus host disease | 3 | MONDO:0013730 | EFO:0004599 |
| hematologic disorder | 3 | MONDO:0005570 | HP:0001871 |
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
| colorectal adenocarcinoma | 2 | MONDO:0005008 | EFO:0000365 |
| aplastic anemia | 2 | MONDO:0015909 | HP:0001915 |
| myelodysplastic syndrome | 2 | MONDO:0018881 | EFO:0000198 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| neoplasm | 1 | MONDO:0005070 | MONDO:0004992 |
| cirrhosis of liver | 0 | MONDO:0005155 | EFO:0001422 |
Clinical trials
Total trials: 14.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
| PHASE1/PHASE2 | 3 |
| PHASE4 | 2 |
| Not specified | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02267993 | PHASE4 | COMPLETED | Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients |
| NCT05217719 | PHASE4 | UNKNOWN | Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients |
| NCT05669079 | PHASE3 | NOT_YET_RECRUITING | Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT |
| NCT06440824 | PHASE3 | NOT_YET_RECRUITING | A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin |
| NCT01319669 | PHASE2/PHASE3 | TERMINATED | Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy |
| NCT03492515 | PHASE3 | UNKNOWN | Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia |
| NCT07400341 | PHASE2 | RECRUITING | Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA |
| NCT00006225 | PHASE1/PHASE2 | COMPLETED | Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer |
| NCT00187109 | PHASE1/PHASE2 | COMPLETED | Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy |
| NCT03014102 | PHASE1/PHASE2 | UNKNOWN | Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation |
| NCT00003597 | PHASE1 | COMPLETED | Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors |
| NCT03673215 | EARLY_PHASE1 | UNKNOWN | The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment |
| NCT00038012 | Not specified | COMPLETED | rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin |
| NCT02281240 | Not specified | UNKNOWN | Hemostatic Complications in Hematopoietic Stem Cell Transplantation |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).